The authors of the high-quality systematic Cochrane Review concluded that the “Review finds no evidence that cannabinoids improve altered behavior in dementia or treat other dementia symptoms” (Krishnan et al., 2009, p. 8). We agree that the evidence is limited […]
The authors of the high-quality systematic Cochrane Review concluded that the “Review finds no evidence that cannabinoids improve altered behavior in dementia or treat other dementia symptoms” (Krishnan et al., 2009, p. 8). We agree that the evidence is limited due to the small number of patients included, limitations of study design and reporting, and inconsistent effects. The currently limited evidence does not support the therapeutic effect of cannabinoids.
This information is often requested by patients who want to control chemotherapy-induced nausea and vomiting without the psychoactive effects of THC-based preparations. A systematic review of good quality was identified (Whiting et al., 2015), who evaluated medical cannabis for the treatment of glaucoma. The study compared THC, cannabidiol, cannabidiol spray and a placebo and examined the intraocular pressure intermittently up to 12 hours after treatment. Increased intraocular pressure is one of the diagnostic criteria for glaucoma, and lowering intraocular pressure is a goal of glaucoma treatment (Prum et al., 2016). Although patients report using cannabinoids for depression, our search for a high-quality systematic review has not identified any RCTs that investigate the effects of medical cannabis on patients with depressive disorders. Studies in patients with chronic pain or multiple sclerosis with uncertain depressive basic symptoms showed no effect.
There is no study data that deals with the effects of cannabinoids in major depressive disorder. We have identified two systematic reviews of randomized trials evaluating the effectiveness of cannabis or cannabinoids used as monotherapy or in addition to other therapies in reducing the frequency of seizures in people with epilepsy. They identified four reports of cannabinoid studies, all of which they considered to be of low quality. The pre-established primary endpoint of the systematic review was seizure-free for 12 months, or three times as long as the longest seizure-free interval before. Consequently, Gloss and Vickrey stated that no reliable conclusions could be drawn about the effectiveness of cannabinoids in epilepsy. The renewed interest in the therapeutic effects of cannabis stems from the movement that began 20 years ago to make cannabis available as a medicine for patients with a variety of medical conditions.
Currently, the only CBD product approved by the Food and Drug Administration is a prescription oil called Epidiolex. While CBD is being studied to treat a variety of conditions, including Parkinson’s, schizophrenia, diabetes, multiple sclerosis and anxiety, research proving the drug’s benefits remains limited. CBD has been highlighted as an effective alternative to traditional treatment options for a variety of health problems, including anxiety, depression, heart disease, inflammation, and neurological disorders. Most of the evidence for health benefits comes from animal studies or smaller studies in humans. The study also led to the FDA’s approval of the first CBD-based anticonvulsant drug – Epidiolex. Both THC and CBD can have a number of benefits, but you should always talk to your doctor before trying a product that contains these cannabinoids.
The Committee did not identify any good quality primary literature that reported on medical cannabis as an effective treatment to improve anxiety symptoms and that was published after the data collection period of the last published systematic review of good or good quality, in which the research topic was covered. Primary Literature The Committee did not identify any good quality primary literature describing cannabis or cannabinoids as effective treatments for AIDS wasting syndrome that was published after Green Roads Review the data collection period of the last published good or good quality systematic review that addressed the research topic. This is mainly due to the virtual disappearance of the syndrome, since effective antiretroviral therapies became available in the mid-1990s. Anxiety disorders and mood disorders such as depression or post-traumatic stress disorder can greatly affect your daily life, often causing physical and emotional stress that can lead to other underlying conditions such as sleep disorders.